DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Zyban (Bupropion Hydrochloride) - Summary

 
 



ZYBAN SUMMARY

ZYBAN (bupropion hydrochloride) Sustained-Release Tablets are a non-nicotine aid to smoking cessation. ZYBAN is chemically unrelated to nicotine or other agents currently used in the treatment of nicotine addiction. Initially developed and marketed as an antidepressant (WELLBUTRIN® [bupropion hydrochloride] Tablets and WELLBUTRIN SR® [bupropion hydrochloride] Sustained-Release Tablets), ZYBAN is also chemically unrelated to tricyclic, tetracyclic, selective serotonin re-uptake inhibitor, or other known antidepressant agents. Its structure closely resembles that of diethylpropion; it is related to phenylethylamines. It is (±)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone hydrochloride.

ZYBAN is indicated as an aid to smoking cessation treatment.


See all Zyban indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Zyban (Bupropion)

FDA Approves Bupropion/Naltrexone (Contrave) for Obesity
Source: Medscape Diabetes & Endocrinology Headlines [2014.09.10]
After a rocky start, the FDA has finally approved the obesity medication, but with a boxed warning about the risk for suicidal thoughts and serious neuropsychiatric events.
FDA Approvals

Third Obesity Drug Wins FDA Okay
Source: MedPage Today Cardiovascular [2014.09.11]
(MedPage Today) -- Following an earlier snub, the FDA finally approved the weight-loss drug Contrave, a combination of bupropion and naltrexone, the agency announced.

Smoking cessation vital to improved Aboriginal birth outcomes
Source: Pregnancy / Obstetrics News From Medical News Today [2014.09.01]
Not smoking during pregnancy is as important for Indigenous women as it is for non-Aboriginal women, but with smoking rates in Aboriginal people three times those of the non-Aboriginal community...

Intervention helps smokers quit following hospital stay
Source: Smoking / Quit Smoking News From Medical News Today [2014.08.19]
Among hospitalized adult smokers who wanted to quit, a postdischarge intervention that included automated telephone calls and free medication resulted in higher sustained smoking cessation rates at...

more news >>

Published Studies Related to Zyban (Bupropion)

The DRD4 Exon III VNTR, Bupropion, and Associations With Prospective Abstinence. [2012]
cognitive-behavioral mood management therapy... CONCLUSIONS: VNTR by treatment interaction

A retrospective analysis of two randomized trials of bupropion for methamphetamine dependence: suggested guidelines for treatment discontinuation/augmentation. [2012]
BACKGROUND: Two clinical trials have shown efficacy for bupropion in treating methamphetamine (MA) dependence among those with moderate baseline MA use. However, treatment response is highly variable and it is unclear what duration of treatment is necessary to determine if maintaining the treatment course is indicated or if discontinuation or augmentation is appropriate.

Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. [2012]
Despite effective therapies for smoking cessation, most smokers find quitting difficult and most successful quitters relapse. Considerable evidence supports a genetic risk for nicotine dependence; however, less is known about the pharmacogenetics of smoking cessation... Different loci are associated with varenicline vs bupropion response, suggesting that additional research may identify clinically useful markers to guide treatment decisions.

Effects of varenicline and bupropion on cognitive processes among nicotine-deprived smokers. [2012]
Nicotine deprivation is associated with craving, negative affect, and difficulty concentrating, which may contribute to subsequent relapse... Identifying these mechanisms may help in the development of new pharmacological treatments.

Bupropion sustained release added to group support for smoking cessation in schizophrenia: a new randomized trial and a meta-analysis. [2012]
CONCLUSIONS: New clinical trial data and a meta-analysis strongly support the

more studies >>

Clinical Trials Related to Zyban (Bupropion)

Wellbutrin XL, Major Depressive Disorder and Breast Cancer [Completed]

- To evaluate the efficacy of bupropion extended release (Wellbutrin XL™) in the treatment

of Major Depressive Disorder in women with breast cancer.

- To evaluate the tolerability of bupropion extended-release (Wellbutrin XL™) in these

patients

Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial [Recruiting]
Patients who continue to smoke after a heart attack have a 35% increased risk of a recurrent event or death compared with those who quit. Many patients attempt to stop smoking after a heart attack, but relapse rates approach 66%. A variety of smoking cessation aids have been shown to be effective for the general population. However, bupropion is the only non-nicotine replacement therapy shown to improve abstinence rates in healthy young smokers. Furthermore, nicotine replacement therapies (NRTs) are contraindicated in the immediate period following a heart attack because of the undesirable effects of nicotine. Although bupropion has been successfully used to reduce smoking rates in healthy young populations, its efficacy and safety in the setting of patients recovering from an ACS is unknown. These patients, if they continue to smoke, are at exceptionally high risk for recurrent cardiac events. If bupropion is effective in this population, it will have a major impact on secondary prevention of recurrent clinical events in patients who suffer a heart attack.

The Effect of Varenicline (Chantix) and Bupropion (Zyban) on Smoking Lapse Behavior [Recruiting]
The purpose of this study is to examine how smoking cessation medications (varenicline, bupropion) affect the ability to resist smoking and also subsequent ad-lib smoking in non-treatment seeking daily smokers.

Concurrent Bupropion / Varenicline for Smoking Cessation [Recruiting]
This study focuses on the first step in developing an algorithm for maximizing quit-smoking success based on an adaptive approach, which changes treatment from the initial NRT (nicotine replacement therapy) when that treatment alone may not be sufficient. These NRT "non-responders" are switched (in double-blind fashion) before the quit date to receive either varenicline (Chantix) alone or varenicline (Chantix) paired with bupropion (Zyban). Some participants who would otherwise have failed at their quit smoking attempt could be "rescued" by switching to alternative pharmacotherapies. The proposed study will evaluate the combination treatment against varenicline alone in an adaptive trial design

Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype [Recruiting]
Nicotine replacement therapy (NRT) is a well-tolerated and efficacious smoking cessation treatment, and yet many smokers fail to quit using NRT. Many of these smokers may benefit from prescription treatment alternatives, including Zyban or Chantix. In this study, the investigators propose to develop and evaluate a stepped-care treatment algorithm that would evaluate whether smokers who receive treatment with NRT should be supplemented with Zyban or switched to Chantix only based on: 1) their initial response to NRT; and 2) individual genetic factors found to predict smoking cessation in other studies evaluating these treatments. This study is a continuation of our previous studies showing that abstinence rates can be increased by starting nicotine patch therapy two weeks before the quit date. The investigators will provide pre-cessation NRT to all participants initially. Those who do not show a favorable response on early indicators of success (e. g., smoking in the first week after the target quit-smoking date) will receive "rescue" treatment by having their NRT treatment supplemented with Zyban , by being switched to treatment with Chantix or will remain on NRT (control).

The investigators hypothesize that "Rescue" treatment with Zyban in combination with NRT or Chantix will increase success rates over leaving subjects on NRT when they are NRT insufficient responders, i. e. they have shown an unfavorable response to NRT in the first week pre-quit or the first week post-quit.

more trials >>

Reports of Suspected Zyban (Bupropion) Side Effects

Urticaria (6)Drug Abuse (4)Pain (3)Drug Interaction (3)DRY Mouth (3)Depression (3)Drug Hypersensitivity (3)Anxiety (3)Insomnia (3)Confusional State (2)more >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 16 ratings/reviews, Zyban has an overall score of 5.56. The effectiveness score is 7.38 and the side effect score is 4.88. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.
 

Zyban review by 38 year old female patient

  Rating
Overall rating:  
Effectiveness:   Highly Effective
Side effects:   Mild Side Effects
  
Treatment Info
Condition / reason:   Smoking Cessation
Dosage & duration:   150mg taken twice daily for the period of 4 Months
Other conditions:   None
Other drugs taken:   Birth Control
  
Reported Results
Benefits:   The drug did exactly what it was supposed to do. It completely eliminated all nicotine cravings leaving only the psychological aspect to worry about. So if I kept myself busy, the thought of smoking would never even enter my mind.
Side effects:   For the first week or so, I was slightly hyperactive and had some trouble sleeping. That problem went away with some adjustment in the time I took the drug as well as with my bodies assimilation of the drug. I also had a mildly bad taste in my mouth. That too faded away.
Comments:   I expressed to my doctor a desire to try this drug to quit smoking. She prescribed it to me and I began taking it shortly thereafter. Before my 2 week quit date had even arrived, I noticed a marked decrease in nicotine withdrawl episodes. I just didn't need to smoke. I found I was started to smoke only when I thought I "should" - after dinner, right before bed and other habitual times. Once I stopped smoking all together, it was a relief to only have to battle my habits and not the withdrawl effects of nicotine as well.

 

Zyban review by 41 year old male patient

  Rating
Overall rating:  
Effectiveness:   Highly Effective
Side effects:   Severe Side Effects
  
Treatment Info
Condition / reason:   smoking
Dosage & duration:   150 mg taken twice daily for the period of 2 months
Other conditions:   none
Other drugs taken:   none
  
Reported Results
Benefits:   it has done its job and i am smoke free now for 10 weeks
Side effects:   had random dreams for about 1 week,the worst thing was not reading the side effects of drinking alcahol,on one accasion had very little to drink and was verry hung over next day not knowing if someone had spiked my drink, the second time when drinking with mates on the town totally blacked out and have no recolection of 5 to six hours of where i had been or what i had done and sleeping for nearly a day being so tired as though you have not slept for a week
Comments:   i have stopped taking them now and still not smoking but would warn all to be aware of what the side effects can be its been about 2 week off them now and still feel a bit panicky drowsy at times

 

Zyban review by 28 year old female patient

  Rating
Overall rating:  
Effectiveness:   Ineffective
Side effects:   Extremely Severe Side Effects
  
Treatment Info
Condition / reason:   to quit smoking
Dosage & duration:   don't recall (dosage frequency: 1 per day) for the period of 10 days
Other conditions:   none
Other drugs taken:   none
  
Reported Results
Benefits:   none
Side effects:   My side effects were severe depression, and alteration in personality. Do not take this drug, the side effects can be severe. I had no previous issues with depression, and as soon as I started taking this drug, I developed severe depression, and changes in my personality. Thankfully, my family noticed a change, and advised me and told me to stop taking Zyban. It took 2 years to overcome the depression and over 3 years to begin to feel like myself again. Stay away from this drug! If you want to quit smoking, butt out and stick to your guns. I quit, and it wan't the Zyban. I have been smoke free for 10 years, and depression free for 7 or 8. Someone should consider a class-action suit against the company which produces this drug. Based on other reviews I have seen, I am not the only one who had these side effects.
Comments:   I took this drug to quit smoking. I am a female and was 28 years old at the time.

See all Zyban reviews / ratings >>

Page last updated: 2014-09-11

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014